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ABSTRACT
Introduction Anticoagulation therapy is pivotal in the 
management of stroke prevention in atrial fibrillation (AF). 
Prospective registries, containing longitudinal data are 
lacking with detailed information on anticoagulant therapy, 
treatment adherence and AF- related adverse events in 
practice- based patient cohorts, in particular for non- 
vitamin K oral anticoagulants (NOAC). With the creation 
of DUTCH- AF, a nationwide longitudinal AF registry, we 
aim to provide clinical data and answer questions on the 
(anticoagulant) management over time and of the clinical 
course of patients with newly diagnosed AF in routine 
clinical care. Within DUTCH- AF, our current aim is to 
assess the effect of non- adherence and non- persistence 
of anticoagulation therapy on clinical adverse events (eg, 
bleeding and stroke), to determine predictors for such 
inadequate anticoagulant treatment, and to validate and 
refine bleeding prediction models. With DUTCH- AF, we 
provide the basis for a continuing nationwide AF registry, 
which will facilitate subsequent research, including future 
registry- based clinical trials.
Methods and analysis The DUTCH- AF registry is a 
nationwide, prospective registry of patients with newly 
diagnosed ‘non- valvular’ AF. Patients will be enrolled 
from primary, secondary and tertiary care practices 
across the Netherlands. A target of 6000 patients for this 
initial cohort will be followed for at least 2 years. Data 
on thromboembolic and bleeding events, changes in 
antithrombotic therapy and hospital admissions will be 
registered. Pharmacy- dispensing data will be obtained 
to calculate parameters of adherence and persistence to 
anticoagulant treatment, which will be linked to AF- related 
outcomes such as ischaemic stroke and major bleeding. In 
a subset of patients, anticoagulation adherence and beliefs 
about drugs will be assessed by questionnaire.
Ethics and dissemination This study protocol was 
approved as exempt for formal review according to 
Dutch law by the Medical Ethics Committee of the Leiden 
University Medical Centre, Leiden, the Netherlands. Results 
will be disseminated by publications in peer- reviewed 
journals and presentations at scientific congresses.
Trial registration number Trial NL7467, NTR7706 
(https://www. trialregister. nl/ trial/ 7464).
Strengths and limitations of this study
 ► The DUTCH- AF registry will provide important in-
sights into the effects of non- adherence and non- 
persistence of anticoagulation therapy on clinically 
adverse outcomes such as stroke and major bleed-
ing. Moreover, it will also provide patient character-
istics of non- adherent and non- persistent patients 
that could be targeted for adherence- improving in-
terventions in the future.
 ► Patients are enrolled from all levels of care across 
the Netherlands including patients from general 
practices and thrombosis services, thereby increas-
ing the generalisability of the study results.
 ► The registry will provide an essential framework for 
improving quality of care and for patient- centred re-
search, including the opportunity for future registry- 
based randomised controlled trials or trials within 
cohort (TWiC) designs.
 ► Extrapolation and generalisability of this registry 
could be limited when patients are enrolled from pri-
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INTRODUCTION
As a consequence of the increasing prevalence of atrial 
fibrillation (AF) in our ageing society, its associated 
adverse events and the overall societal healthcare burden, 
there is a need for optimisation of AF management.1 
Collecting data on case- mix, treatment and outcomes of 
AF patients has been shown to be valuable for improving 
the management of AF patients.2–4
DUTCH- AF is a nationwide, prospective registry 
designed to gather information on the (anticoagulation) 
management and clinical course of patients with newly 
diagnosed AF. Virtually all newly diagnosed AF patients 
in the Netherlands are eligible for this registry, and 
patients will be included throughout all levels of care. By 
collecting these data, DUTCH- AF will provide a base for 
future research (notably registry- based randomised trials) 
and will provide benchmark data for care providers. This 
will strengthen the cooperation between different care 
providers and improve quality of AF care and research.
Aside from collecting registry data, a prospective study 
assessing non- adherence and non- persistence to anticoag-
ulation therapy in this AF population will be performed 
simultaneously, under the hypothesis that non- adherence 
and non- persistence to anticoagulation therapy increases 
the risk of AF- related and anticoagulant- related adverse 
events, such as stroke and bleeding. As a recent meta- 
analysis has shown, primary therapy non- adherence 
is frequently seen in common chronic diseases.5 For 
instance, in patients with therapy- resistant hypertension, 
non- adherence was seen in over two- thirds of patients.6 In 
line with these findings, multiple studies have shown in 
recent years that non- adherence and non- persistence to 
anticoagulation therapy occur frequently in AF patients 
as well, which subsequently affects safety and efficacy 
outcomes negatively.7–12 Based on these findings, identi-
fying predictors of non- adherence and non- persistence 
is highly needed, as these patients could be targeted for 
adherence- improving interventions in the future.
Furthermore, one important complication of anti-
coagulation therapy, which could also affect patient 
adherence and persistence, is bleeding. Identifying AF 
patients with high risk of bleeding could potentially help 
decision- making and follow- up strategies in anticoagu-
lant management, in particular to flag or identify poten-
tially modifiable risk factors for bleeding. Unfortunately, 
existing AF bleeding prediction models perform moder-
ately well and have few clinical implications.3 13–16
With this prospective study, DUTCH- AF aims to (i) 
determine the clinical impact of non- adherence and non- 
persistence to anticoagulation therapy in AF patients, 
(ii) identify predictors for non- adherence and non- 
persistence to oral anticoagulants (OAC) therapy, and 
(iii) validate and refine current bleeding prediction 
models.
By combining subsequent research with a quality 
registry, DUTCH- AF aims to provide important insights 
into contemporary (anticoagulation) management of 
AF and the clinical impact of non- adherence and non- 
persistence to anticoagulation therapy.
METHODS
Design
DUTCH- AF is a prospective, observational, multicentre, 
nationwide study of a representative sample of Dutch 
patients with newly diagnosed AF. The registry started as 
of January 2018, with a planned 3 years of patient recruit-
ment. The intended duration of patient follow- up will be 
at least 2 years.
DUTCH- AF is an integral part of a nationwide cardio-
vascular data registration strategy. The creation of this 
nationwide registry was conducted in collaboration with 
the Netherlands Society of Cardiology (NVVC), the Neth-
erlands Association of Cardiothoracic Surgery (NVT), 
the Dutch College of General Practitioners (NHG), the 
Netherlands Heart Registry (NHR) and the Dutch Heart 
Foundation. Prior experience of the Netherlands Heart 
Network (NHN) was incorporated in the design as well.17 
The data gathered in DUTCH- AF is managed by the NHR 
and will be the basis of a continuous, ongoing AF registry, 
enabling the possibility to conduct registry- based trials by 
applying the trials within cohort (TWiC) design.18–20 This 
is done with the ambition to enhance scientific evaluation 
in AF research, and bring valuable, promising interven-
tions easier and faster to patients at lower study costs and 
burden.
Study population
Investigators enrol consecutive patients aged ≥18 years 
with newly diagnosed non- valvular AF (initial AF diag-
nosis <6 months before the inclusion date). Patients with 
valvular AF (ie, moderate- to- severe mitral stenosis or a 
mechanical heart valve), an anticipated life expectancy 
<6 months or with documented AF developing within 
14 days after cardiothoracic surgery will be excluded. AF 
following cardiothoracic surgery is an exclusion criterion 
for this registry due to its high incidence (in 20% to 40% 
of all surgeries) and its self- limiting nature (80% revert 
back to sinus rhythm within 24 hours).21 22 All patients 
are asked to provide written informed consent for partic-
ipation and permission (i) to collect their baseline and 
predefined follow- up data, (ii) to be approached for 
future studies, for example, registry- based trials (TWiC 
design), and (iii) for participation in a paper survey on 
anticoagulation adherence and beliefs about drugs.
Site selection
Sites from all over the Netherlands participate in this 
registry, consisting of but not limited to a broad mix of 
hospitals (secondary and tertiary centres), anticoagula-
tion clinics and general practitioner (GP) practices. All 
Dutch centres treating AF patients are encouraged to join 
the registry. Centres are informed on the registry through 
symposia, newsletters, mailings and word of mouth with 
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Clinics (FNT), NVVC, NHR, general practitioner networks 
and NVVC Connect- AF. In this way, we aim to enrol a 
representative sample of all Dutch newly diagnosed AF 
patients, minimising selection and allowing for a broad 
generalisability of findings.
Data collection and follow-up
Data will be primarily collected from electronic medical 
records of the enrolled patients, and will mainly consist 
of routine care data. At baseline, data will be collected on 
patient demographics, pattern of AF, date and location 
of the initial AF diagnosis, secondary causes of AF, Euro-
pean Heart Rhythm Association (EHRA) classification, 
relevant medical history with items that contribute to the 
CHA2DS2- VASc score (Congestive heart failure, Hyper-
tension, Age ≥75, Diabetes mellitus, Stroke/TIA/throm-
boembolism, Vascular disease, Age 65-74, Sex category 
(ie, female sex)) and bleeding risk assessment, and the 
(cardiovascular) medical treatment.23 Follow- up is sched-
uled at 12 and 24 months after inclusion. At follow- up, 
data will be collected from electronic medical records, 
accompanied by telephone interviews. Follow- up data will 
be complemented with pharmacy dispensing data from 
the Foundation for Pharmaceutical Statistics (SFK).24 
Box 1 provides an overview of the data collected during 
baseline and follow- up. Table 1 provides an overview of 
the causes of secondary AF.23
Outcomes
The following clinical outcomes will be registered during 
follow- up: (i) thromboembolic adverse events (ie, tran-
sient ischaemic attack, ischaemic stroke, arterial throm-
botic event and myocardial infarction), (ii) bleeding (ie, 
major, clinically relevant non- major bleeding (CRNMB) 
and minor bleeding), (iii) AF- related visits to the emer-
gency department or hospital admissions, (iv) all changes 
in antithrombotic therapy, (v) adherence to antithrom-
botic therapy, and (vi) all- cause mortality. Outcome defi-
nitions of all major cardiovascular and bleeding endpoints 
will be assessed as stated in online supplementary table 
1.16 25 26 Thromboembolic adverse events, clinically rele-
vant bleeding and myocardial infarction will be judged 
by a blinded, independent adjudication committee, 
consisting of a neurologist, a cardiologist and a vascular 
internist.
Data on adherence and persistence to OAC will be 
acquired in two ways. First, the SFK, which has a coverage 
of >95% of all community pharmacies, will provide medi-
cation dispensing data of all included patients.24 Adher-
ence and persistence rates to OAC will be calculated using 
these data. The various measures are explained in the 
Statistical Analysis section. Second, a subset of patients 
will be sent a composite questionnaire regarding antico-
agulation adherence and beliefs about drugs at one point 
in time. The composite questionnaire consists of the 
Beliefs about Medicines Questionnaire (BMQ), the Medi-
cation Adherence Report Scale (MARS-5) and the Dutch 
General Self- Efficacy Scale (DGSS).27–30 The composite 
questionnaire is sent randomly after 1, 6, 12 or 24 months 
after inclusion if patients (1) agreed to participate when 
consulted at inclusion, and (2) used antithrombotic 
therapy within 1 month after inclusion. Table 2 provides 
an overview of the various items asked in the question-
naires.27–29 31
Data management
All clinical data are accumulated using a web- based Elec-
tronic Data Capture System and are registered in elec-
tronic case report forms (e- CRF). All e- CRF records will 
be pseudonymised and patients are assigned a unique 
study identifier. Personal data of all included patients 
will be collected to send the composite questionnaire on 
Box 1 Overview of baseline and follow- up variables
Baseline
Demographics: gender, age and ethnicity
Weight, height and blood pressure
Recent haemoglobin and kidney function
Medical history: all parameters included in CHA
2DS2- VASc, sleep ap-
noea, chronic lung disease, malignancy and prior bleeding history
Date of AF diagnosis
Location of AF diagnosis: primary or specialist care
Complaints of AF: EHRA symptom classification
Pattern: paroxysmal or persistent AF
Treatment: none, rhythm or rate control
Secondary causes of AF: infection/inflammation, non- cardiothoracic 
surgery, MI, alcohol consumption, thyrotoxicosis, pericardial and myo-
cardial disease and acute pulmonary embolism
Anticoagulation prior to AF diagnosis: none, antiplatelet agents, VKA 
and/or NOAC
Anticoagulation after AF diagnosis: none, antiplatelet agents, VKA and/
or NOAC
Follow- up
Weight and blood pressure
Recent haemoglobin and kidney function
Pattern: paroxysmal, persistent, long- standing persistent and perma-
nent AF
Occurrence of bleeding events:
 ► Severity: MB, CRNMB
 ► Location: intracranial, intraspinal, intraocular, retroperitoneal, intra- 
articular or pericardial, intramuscular, gastrointestinal, urogenital, 
nasal and pulmonary.
Occurrence of ischaemic events: TIA, ischaemic stroke, ATE and MI
Healthcare utilisation: emergency department visits or hospital admis-
sion for AF treatment
Side effects to antiarrhythmic treatment
Changes in anticoagulation treatment and CHA
2DS2- VASc
Prescription data from SFK:
 ► Dispensing data (type and dosage)
 ► Concomitant medical therapy
Adherence and persistence
In a subset of patients: MARS-5/BMQ/DGSS questionnaires
ATE, arterial thrombotic event; BMQ, Beliefs about Medicines Questionnaire; 
CRNMB, clinically relevant non- major bleeding; DGSS, Dutch General Self- 
Efficacy Scale; EHRA, European Heart Rhythm Association; MARS-5, Medication 
Adherence Report Scale; MB, major bleeding; MI, myocardial infarction; 
NOAC, non- vitamin K oral anticoagulants; SFK, Foundation of Pharmaceutical 
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medication adherence and beliefs about drugs, for linkage 
with the SFK and for approach of the patients for future 
research. All personal data will be handled according to 
the General Data Protection Regulation (GDPR) and the 
Dutch Act on Implementation of the GDPR, and will be 
stored separately from the e- CRF. By using an application 
for the storage of personal data, the risk of including the 
same patient twice is negligible. Data monitoring will be 
performed by the coordinating researchers to ascertain 
completeness and accuracy of the entered data. Source 
data verification will be undertaken in 1% to 10% of 
all cases. A comprehensive plan has been developed to 
monitor the quality of data entered into the electronic 
database during the course of the programme. Linkage 
of the pharmacy dispensing data with the corresponding 
study participants will be performed by a trusted third 
party using pseudonymised data.
Statistical analysis
Research aim 1: association between OAC adherence/persistence, 
dosage and clinical outcomes
To evaluate adherence and persistence of non- vitamin K 
oral anticoagulants (NOACs), subsequent dispensing of 
NOACs will be assessed. If the prior prescription ended 
prior to the subsequent dispensing date, it would be 
considered a gap. The length of the gap will be measured 
in days. To improve the accuracy of our adherence 
assessment, we will correct for patients stacking their 
medication at home, and account for the carry- over of 
oversupply. Patient adherence to NOAC will be expressed 
through the medication possession rate (MPR) and the 
proportion of days covered (PDC). The PDC is obtained 
by dividing the number of daily doses dispensed from the 
first prescription until, but not including, the last refill 
with the number of days in that interval and expressed 
as a percentage. Patients will be classified as adherent or 
non- adherent dependent on various PDC cut- off points, 
including the PDC >80%, in line with previous publi-
cations.32 Other measures of patient adherence will be 
assessed, including the gap length and the total gap days. 
As a proxy of patient adherence to vitamin K antago-
nist (VKA), patient adherence to VKA will be expressed 
through the time in therapeutic range (TTR) of interna-
tional normalized ratio (INR). Patients will be classified 
as adherent dependent on various TTR cut- off points. 
The TTR will be calculated with the Rosendaal method.33
Persistence will be defined as the time, in days, between 
the first dispension and until the day of treatment 
discontinuation. As patients can switch to another anti-
coagulant therapy, we will assess persistence to the 
prescribed anticoagulant in particular and to antico-
agulant therapy in general as well. Persistence rates for 
both VKA and NOACs will be calculated for various time 
intervals. Kaplan- Meier curves will be used to graphically 
display persistence over time.
OAC adherence and persistence will be linked to 
risks of both thromboembolic and bleeding outcomes. 
First, patients with such occurrences will be matched 
with patients without occurrences on time, since start 
of follow- up. We will classify adherence and persistence 
measures as described above. ORs with 95% CI will be 
calculated using conditional multivariate logistic regres-
sion to assess the association between adherence and 
persistence to the anticoagulation therapy and the risk 
of event.
Research aim 2: predictors of NOAC non-adherence/non-
persistence
NOAC non- adherence will first be defined as a PDC below 
80%, similarly as above. Next, using this binary outcome, 
a logistic model is fitted to quantify correlations of clinical 
variables with NOAC non- adherence. From the collected 
data, the following variables are considered, based on 
clinical likeliness to be correlated with NOAC- adherence: 
age, sex, comorbidity and comedication.34 This list of 
variables that potentially correlate with NOAC adherence 
will continuously be expanded based on the latest publi-
cations regarding this subject. As clinical outcomes, such 
as bleeding or thromboembolism, may affect adherence 
and persistence afterwards, secondary analyses will be 
performed in which the impact of such clinical outcomes 
on adherence and persistence measures will be assessed. 
Furthermore, we will assess whether the predictors of non- 
adherence prior to or after an event differ. If the impact 
of such clinical outcomes on adherence are of relevance, 
we will perform similar prediction analyses considering 
only the PDC measures prior to or without an event. 
Missing values are imputed using existing multiple impu-
tation techniques and subsequently pooled using Rubin’s 
rule, assuming that the missing at random assumption is 
met. Using backward selection, variables are eliminated 
from the list of potential predictors if they do not have 
independent predictive ability in the model (criterion 
p<0.15). To prevent overfitting, we will apply bootstrap-
ping techniques. Model performance is subsequently 
assessed by estimations of the discriminative power of 
Table 1 Definition of secondary AF used in the DUTCH- AF registry
Secondary AF AF that is triggered within 14 days after (1) infection or inflammation, (2) non- cardiothoracic surgery, 
(3) myocardial infarction, (4) pericarditis/myocarditis, (5) exacerbation chronic pulmonary disease, (6) 
hyperthyroidism, (7) pulmonary embolism, (8) cardiac tamponade or (9) acute alcohol intoxication.
If AF was triggered by any amount of alcohol use, as stated in the medical records by the treating physician, 
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Table 2 Questionnaires for the assessment of patients’ beliefs, attitudes and behaviour regarding anticoagulants in English 
and Dutch language
Beliefs about Medicine Questionnaire specific (BMQ- S)
This 11- item scale asks the patient to rate their beliefs regarding anticoagulation therapy. Respondents indicate their degree of agreement with each statement on a 5- point 
Likert scale, ranging from 1=strongly disagree to 5=strongly agree. Scores obtained for individual items are summed and divided by the total number of items in the scale to 
give a scale score of 1 to 5. Higher scores indicate stronger beliefs.
1. My health at present depends on my anticoagulation therapy
In Dutch: Op het moment hangt mijn gezondheid af van mijn bloedverdunners
2. Having to take anticoagulants worries me.
In Dutch: Ik maak me zorgen over het feit dat ik bloedverdunners moet nemen.
3. My life would be impossible without anticoagulants
In Dutch: Mijn leven zou erg moeilijk zijn zonder bloedverdunners
4. I sometimes worry about the long- term effects of anticoagulation therapy
In Dutch: Soms maak ik me zorgen over de effecten die mijn bloedverdunners op de lange termijn kunne hebben
5. Without anticoagulation therapy, I would be very ill
In Dutch: Zonder mijn bloedverdunners zou ik heel ziek zijn
6. My anticoagulation therapy is a mystery to me
In Dutch: Ik ben onvoldoende op de hoogte van wat mijn bloedverdunners doen
7. My health in the future depends on anticoagulation therapy
In Dutch: Mijn toekomstige gezondheid hangt af van mijn bloedverdunners
8. My anticoagulation therapy disrupts my life
In Dutch: Mijn bloedverdunners ontwrichten mijn leven
9. I sometimes worry about becoming too dependent on anticoagulants
In Dutch: Soms ben ik bang dat ik te afhankelijk zal worden van mijn bloedverdunners
10. Anticoagulation therapy protects me from becoming worse
In Dutch: Mijn bloedverdunners voorkomen dat ik verder achteruit ga
11. This anticoagulation therapy cause me unpleasant side effects
In Dutch: Deze bloedverdunners hebben onplezierige bijwerkingen
Medication Adherence Report Scale, 5- item (MARS-5)
This 5- item scale asks the patient to rate the frequency with which he/she engages in each of the five aspects of non- adherent behaviour. Each item is rated on a 5- point Likert 
scale, where 1=always to 5=never. Score for each of the five items are summed and divided by five to give a scale score of 1 to 5, where higher scores indicate higher levels of 
reported adherence.
1. I forget to take my anticoagulants
Ik vergeet mijn bloedverdunners in te nemen
2. I modify the doses of my anticoagulants
Ik wijzig de dosering van mijn bloedverdunners
3. I stop taking medications during a certain period
Ik stop een tijdje met bloedverdunners te nemen
4. I decide to miss a dose
Ik besluit een dosering over te slaan
5. I take less than what is prescribed
Ik neem minder dan is voorgeschreven
Dutch General Self- efficacy Scale (DGSS)
The DGSS is a 10- item Likert- type scale, where 1=is not true at all to 4=exactly true, that assesses general self- efficacy. Higher scores represent higher levels of general self- 
efficacy
1. I can always manage to solve difficult problems if I try hard enough
Het lukt me altijd om moeilijke problemen op te lossen, als ik er genoeg moeite voor doe
2. If someone opposes me, I can find the means and ways to get what I want
Als iemand mij tegenwerkt, vind ik toch manieren om te krijgen wat ik wil
3. It is easy for me to stick to my aims and accomplish my goals
Het is voor mij makkelijk om vast te houden aan mijn plannen en mijn doel te bereiken
4. I am confident that I could deal efficiently with unexpected events
Ik vertrouw erop dat ik onverwachte gebeurtenissen doeltreffend aanpak
5. Thanks to my resourcefulness, I know how to handle unforeseen situations
Dankzij mijn vindingrijkheid weet ik hoe ik in onvoorziene situaties moet handelen
6. I can solve most problems if I invest the necessary effort
Ik kan de meeste problemen oplossen als ik er de nodige moeite voor doe
7. I can remain calm when facing difficulties because I can rely on my coping abilities
Ik blijf kalm als ik voor moeilijkheden kom te staan omdat ik vertrouw op mijn vermogen om problemen op te lossen
8. When I am confronted with a problem, I can usually find several solutions
Als ik geconfronteerd word met een probleem, heb ik meestal meerdere oplossingen
9. If I am in trouble, I can usually think of a solution
Als ik in een benarde situatie zit, weet ik meestal wat ik moet doen
10. I can usually handle whatever comes my way
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the model (Harrell’s C- statistic, graphically illustrated in 
receiver operating characteristic (ROC) space) and its 
calibration, illustrated in a calibration plot (predicted 
against observed risk).
Research aim 3: validation of bleeding models
All variables of actiVe cancer, male gender with uncon-
trolled hyperTension, anaEmia, history of BLeeding, 
agE ≥60 years and rEnal Dysfunction (VTE- BLEED) 
will be included in the study database in accordance 
with the definitions used in the derivation study.35 Next, 
for each individual patient, predicted risk of the VTE- 
BLEED model will be calculated using the intercept and 
beta’s from the original derivation study. Subsequently, 
as mentioned previously, model performance of VTE- 
BLEED is assessed by quantifying its discriminative power 
(Harrell’s C- statistic, graphically illustrated in ROC 
space) and its calibration, illustrated in a calibration plot 
(predicted against observed risks). Finally, to quantify the 
ability to predict the risk of major bleeding, we will run 
univariate logistic regression models with major bleeding 
as binary outcome. Hereto, ORs and 95% CI are obtained 
for the VTE- BLEED high- risk score class (threshold >2) 
versus low- risk class serving as the reference group.
Should model performance of VTE- BLEED be disap-
pointing (given that VTE- BLEED models was originally 
derived to predict bleeding complications in patients 
with venous thromboembolism, this may occur), simple 
updating techniques will be applied to optimise model 
performance for use in AF patients (rather than devel-
oping a new model). The may include, with increasing 
complexity, an adjustment of the intercept of the model, 
re- estimating the beta’s for the variables from the original 
regression model or including novel variables if needed.
Study size
The registry has a target enrolment of 6000 patients with 
a follow- up of at least 2 years. We expect 5500 NOAC 
users. Based on a 1 year non- persistence in one- third of 
the NOAC users, 1815 patients on NOACs will be non- 
persistent.36 If we assume a 50% increased risk of isch-
aemic stroke/systemic embolism in these patients, we can 
expect on average a 3% yearly risk compared with the 
2% in the 3685 patients who will continue to use their 
drug.7 During 2- year follow- up, we expect 250 patients 
will develop ischaemic stroke/systemic embolism.
If we assume 30% of the remaining NOAC users to 
be non- adherent, we can expect 1105 non- adherent 
NOAC users. With an expected yearly risk of 3.5% major 
bleeding in adherent patients and a 2.5% for non- 
adherent patients, we expect 176 major bleeding events 
annually.37–39 For cardiovascular death, we expect a risk of 
about 1.5% in all NOAC users, leading to 135 deaths in 2 
years. Therefore, we expect a total of about 600 patients 
meeting one of our pre- specified major cardiovascular 
endpoints consisting of ischaemic stroke/systemic embo-
lism, major bleeding including intracranial bleeds and 
all- cause mortality. These numbers will be sufficient to 
(i) determine risk groups, (ii) construct a prediction 
model for non- adherence, and (iii) validate and develop 
bleeding risk scores.
Administrative structure
A steering committee (SC), comprised of experts in 
cardiology, vascular medicine, pharmaceutics and medi-
cation adherence, neurology, general practice and epide-
miology, is responsible for the study design and study 
conduct. A user committee, together with the NHR and 
the SC, evaluates and oversees the inclusion of patients 
and follow- up within the registry.
Patient and public involvement
Two patient advisory groups are involved in DUTCH- AF. 
Harteraad was involved in the grant application process 
for funding from The Netherlands Organisation for 
Health Research and Development (ZonMw). The Cliën-
tenraad Nederlandse Trombosediensten (CTDN) has 
joined the SC of DUTCH- AF. At the end of the study, the 
patient advisory groups will be involved to present the 
results to their peers and patient groups.
ETHICS AND DISSEMINATION
The Medical Ethics Review Committee of Leiden Univer-
sity Medical Centre approved this study and concluded 
that the (Dutch) Medical Research Involving Human 
Research Act (WMO) does not apply, as strictly speaking, 
no experimental interventions are studied or imposed 
on patients. The study is conducted in accordance with 
the Declaration of Helsinki, the Guideline for Good 
Clinical Practice and local regulatory requirements. All 
patients provide written consent to participate after being 
informed about the study. Participants are free to with-
draw at any time. This study is registered in the Nether-
lands Trial Register (Trial NL7467, NTR7706). Results of 
the study will be disseminated to healthcare professionals 
and to the scientific community, through publications in 
peer- reviewed journals as well as presentations at scien-
tific congresses.
DISCUSSION
In the DUTCH- AF registry, baseline characteristics, 
current anticoagulant treatment practices, medication 
adherence and clinical outcome of real- life AF patients 
in the Netherlands will be described. Data are collected 
from newly diagnosed patients with AF. Patients will be 
represented across all levels of care in the Netherlands, 
irrespective of treatment strategies.
In cooperation with the NHR, this registry constitutes 
an essential framework for improving the quality of care 
and for patient- centred research, including the opportu-
nity of registry- based randomised controlled trials (RCT). 
Participating centres can continuously evaluate and 
benchmark their current practice on guideline imple-
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data set has been designed to minimise registration 
burden, but will be sufficient for answering important 
current and future research questions. In the near future, 
our minimal data set will be implemented in Dutch elec-
tronic medical records to minimise double- registration. 
This will improve the quality of the continuing quality 
registry, as the data set will be entered by healthcare 
professionals, instead of using traditional methods with 
disease or treatment codes. The incorporation of the 
DUTCH- AF registry within the centralised network struc-
ture of the NHR will allow for cross- talk between regis-
tries through data linkage and through the adoption of 
a standardised set of definitions. Data collected for the 
AF registry could provide valuable information for other 
registries in which a patient is enrolled, without the need 
for additional follow- up.
A strong feature of this registry includes the inclusion 
of patients from all levels of care across the Netherlands, 
including patients from general practices. In the Nether-
lands, most AF patients will be referred back to the GP 
after the initial management by a cardiologist. The GP 
will have the responsibility for further AF care, including 
routine monitoring of anticoagulant adherence, kidney 
function and side effects, to ensure safe continuation 
of anticoagulation therapy. The participation of general 
practices will provide further information on patients 
who are never referred to specialist care, which are 
presumably more ‘frail’ and at an increased risk of stroke 
and bleeding.
The registry will also provide insights into the effects 
of (non- )adherence and persistence of the anticoagu-
lant therapy on clinical adverse outcomes such as stroke 
and major bleeding. Current guidelines on NOACs are 
predominantly based on the NOAC RCTs, which showed 
high discontinuation rates despite stringent moni-
toring.40–43 Recent observational data showed similar or 
higher rates of discontinuation.44 45 Due to the short half- 
life of NOACs, interruptions are suggested to increase the 
risk for strokes, as was seen in historical VKA studies.46–49 
However, long- term prospective studies assessing the 
effects of non- adherence to NOACs on adverse outcomes 
are lacking. Hence, DUTCH- AF is essential for providing 
patient- based information on adherence/persistence and 
dosage of anticoagulant treatment with NOACs in daily 
practice.
There are inherent limitations to this registry due to 
its design. First, the minimal data set of this registry is 
designed to specifically answer the predefined research 
aims regarding dosing, adherence and persistence of 
anticoagulants. To minimise registration burden, concise 
echocardiographic data were for example not regis-
tered. Furthermore, interpreting differences in outcome 
between hospitals or between the different (anticoagu-
lant) treatment modalities must be done with caution. 
Confounding by indication cannot be entirely captured 
in the minimal data sheet. Also, recall bias can occur 
during the telephone conversation with the patient as part 
of follow- up. Besides, there is a risk of misclassification 
(this risk will, however, be minimised by monitoring of 
the data as prescribed before). Another potential pitfall 
could occur when patients are not equally enrolled from 
primary and secondary/tertiary care, which could limit 
the extrapolation and generalisability of this registry.
The feasibility to derive a prediction model for VKA 
non- adherence will be determined by the number of 
novel AF patients treated with VKA. In the Netherlands, 
NOACs have overtaken VKA as the primary anticoag-
ulant, with the number of starters on VKA decreasing 
rapidly.37 Hence, deriving a prediction model for VKA 
non- adherence was not stated as a research aim; the feasi-
bility of such an analysis will have to be assessed in the 
future.
Finally, as no other study uses the same methods to 
assess dosing, adherence and persistence of anticoagu-
lants in AF patients, future external validation could, for 
example, be performed in patients included after the 
required 6000 patients. Options for external validation in 
other studies or registries will have to be assessed in the 
future, based on the comparability between study designs 
and aims.
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